Literature DB >> 31960518

Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.

Lennard J M Dekker1, Suying Wu1, Cherise Jurriëns1, Dana A N Mustafa2, Frederieke Grevers2, Peter C Burgers1, Peter A E Sillevis Smitt1, Johan M Kros2, Theo M Luider1.   

Abstract

The discovery of the IDH1 R132H (IDH1 mut) mutation in low-grade glioma and the associated change in function of the IDH1 enzyme has increased the interest in glioma metabolism. In an earlier study, we found that changes in expression of genes involved in the aerobic glycolysis and the TCA cycle are associated with IDH1 mut. Here, we apply proteomics to FFPE samples of diffuse gliomas with or without IDH1 mutations, to map changes in protein levels associated with this mutation. We observed significant changes in the enzyme abundance associated with aerobic glycolysis, glutamate metabolism, and the TCA cycle in IDH1 mut gliomas. Specifically, the enzymes involved in the metabolism of glutamate, lactate, and enzymes involved in the conversion of α-ketoglutarate were increased in IDH1 mut gliomas. In addition, the bicarbonate transporter (SLC4A4) was increased in IDH1 mut gliomas, supporting the idea that a mechanism preventing intracellular acidification is active. We also found that enzymes that convert proline, valine, leucine, and isoleucine into glutamate were increased in IDH1 mut glioma. We conclude that in IDH1 mut glioma metabolism is rewired (increased input of lactate and glutamate) to preserve TCA-cycle activity in IDH1 mut gliomas.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals, Inc. on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  IDH1 mutation; TCA cycle; glioma; glutaminolysis; metabolism; proteomics

Year:  2020        PMID: 31960518     DOI: 10.1096/fj.201902352R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  Metabolism-Associated DNA Methylation Signature Stratifies Lower-Grade Glioma Patients and Predicts Response to Immunotherapy.

Authors:  Guozheng Yang; Dezhi Shan; Rongrong Zhao; Gang Li
Journal:  Front Cell Dev Biol       Date:  2022-06-15

2.  Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair.

Authors:  Tsung-Chih Chen; Chi-Yuan Yao; Yu-Ren Chen; Chang-Tsu Yuan; Chien-Chin Lin; Yueh-Chwen Hsu; Po-Han Chuang; Chein-Jun Kao; Yi-Hung Li; Hsin-An Hou; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Oncogene       Date:  2022-01-28       Impact factor: 8.756

3.  Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.

Authors:  Christian Linke; Markus Wösle; Anja Harder
Journal:  BMC Cancer       Date:  2020-09-18       Impact factor: 4.430

Review 4.  Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Authors:  Cornelis J F van Noorden; Vashendriya V V Hira; Amber J van Dijck; Metka Novak; Barbara Breznik; Remco J Molenaar
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600

5.  Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures.

Authors:  Cassandra Verheul; Ioannis Ntafoulis; Trisha V Kers; Youri Hoogstrate; Pier G Mastroberardino; Sander Barnhoorn; César Payán-Gómez; Romain Tching Chi Yen; Eduard A Struys; Stijn L W Koolen; Clemens M F Dirven; Sieger Leenstra; Pim J French; Martine L M Lamfers
Journal:  Neurooncol Adv       Date:  2021-08-02

6.  Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures.

Authors:  Lennard J M Dekker; Cassandra Verheul; Nicky Wensveen; William Leenders; Martine L M Lamfers; Sieger Leenstra; Theo M Luider
Journal:  ACS Omega       Date:  2022-01-19

Review 7.  Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.

Authors:  Ingvild Comfort Hvinden; Tom Cadoux-Hudson; Christopher J Schofield; James S O McCullagh
Journal:  Cell Rep Med       Date:  2021-12-21

Review 8.  Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond.

Authors:  Abdellatif El Khayari; Najat Bouchmaa; Bouchra Taib; Zhiyun Wei; Ailiang Zeng; Rachid El Fatimy
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

9.  Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.

Authors:  Kenta Suzuki; Nobuyuki Kawai; Tomoya Ogawa; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2021-07-21       Impact factor: 3.138

Review 10.  Mitochondria Targeting as an Effective Strategy for Cancer Therapy.

Authors:  Poorva Ghosh; Chantal Vidal; Sanchareeka Dey; Li Zhang
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.